Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

Exclusion Criteria

• •Pregnant women
• •Incarcerated patients
• •Life expectancy less than 72 hours
• •Severe bleeding at time of enrollment
• •HIV, sepsis, intracranial bleeding, congenital disorder, anti-phospholipid antibody syndrome or known lupus anticoagulant antibodies
• •Receipt of plasma products, coagulation factor concentrates or anti-platelets within 3 days of enrollment
• •Specific factor inhibitor activity or history of hypersensitivity to plasma-derived products
• •Receipt of iv heparin within 24 hours of enrollment
• •Use of a continuous infusion of an intravenous vasoactive medication
• •Thrombocytopenia
• •BMI greater than or equal to 40 kg/m2
• •Participation in another clinical trial within 30 days of enrollment and received investigational product that may impact safety or efficacy of this study
• •West Haven Hepatic Encephalopathy Grade 3 or 4 (cohort 1) and Grade 4 (cohort 2)